OverviewSuggest Edit

Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer. Its technologies allow creating humanized antibodies that can be used either alone in unlabeled or naked form or conjugated with radioactive isotopes, chemotherapeutics, cytokines, or toxins.

TypePublic
Founded1982
HQMorris Plains, US
Websiteimmunomedics.com
Employee Ratings2.8

Latest Updates

Employees (est.) (Dec 2019)366(+6%)
Job Openings39
Revenue (FY, 2019)$295 K(-86%)
Share Price (Sept 2020)$85.3
Cybersecurity ratingCMore

Key People/Management at Immunomedics

Behzad Aghazadeh

Behzad Aghazadeh

Executive Chairman of the Board of Directors
Usama Malik

Usama Malik

Chief Financial Officer, Chief Business Officer
Brendan Delaney

Brendan Delaney

Chief Commercial Officer
Kurt Andrews

Kurt Andrews

Chief Human Resources Officer
Jared Freedberg

Jared Freedberg

General Counsel and Corporate Secretary
Bryan Ball

Bryan Ball

Chief Quality Officer
Show more

Immunomedics Office Locations

Immunomedics has offices in Morris Plains and Rödermark
Morris Plains, US (HQ)
300 The American Rd
Rödermark, DE
Paul-Ehrlich-Straße 22/D1
Show all (2)

Immunomedics Financials and Metrics

Immunomedics Revenue

Embed Graph
View revenue for all periods
Immunomedics's revenue was reported to be $295 k in FY, 2019 which is a 86.3% decrease from the previous period.
USD

Revenue (Q2, 2020)

20.1m

Gross profit (Q2, 2020)

18.4m

Gross profit margin (Q2, 2020), %

91.7%

Net income (Q2, 2020)

(66.5m)

EBIT (Q2, 2020)

(53.0m)

Market capitalization (17-Sept-2020)

19.7b

Closing stock price (17-Sept-2020)

85.3

Cash (30-Jun-2020)

971.2m

EV

18.8b
Immunomedics's current market capitalization is $19.7 b.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

3.1m2.2m295.0k

Revenue growth, %

(4%)(30%)(86%)

Cost of goods sold

482.7k613.6k

Gross profit

2.6m1.5m295.0k
Half Year
USDH2, 2018

Sales and marketing expense

19.8m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

690.5k597.3k482.2k20.1m

Cost of goods sold

70.2k496.6k46.8k1.7m

Gross profit

620.3k100.7k435.4k18.4m

Gross profit Margin, %

90%17%90%92%
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

43.4m612.1m608.6m

Accounts Receivable

488.7k45.8k295.0k

Prepaid Expenses

891.3k3.8m21.8m

Inventories

580.0k
Half Year
USDH2, 2018

Cash

492.9m

Prepaid Expenses

5.4m

Current Assets

504.5m

PP&E

23.5m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

43.0m61.0m306.7m580.6m437.9m427.9m364.7m536.3m971.2m

Accounts Receivable

427.2k343.3k195.0k22.3m

Prepaid Expenses

5.1m4.7m4.3m8.5m4.9m8.3m7.6m17.3m21.1m

Inventories

527.7k43.3k20.8m
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(153.3m)(273.9m)(357.3m)

Depreciation and Amortization

923.3k1.3m3.8m

Inventories

(196.0k)580.0k

Accounts Payable

15.8m(1.5m)30.0m
Half Year
USDH2, 2018

Net Income

(157.7m)

Depreciation and Amortization

2.1m

Accounts Payable

1.4m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(118.8m)(121.3m)(156.8m)(64.2m)(87.4m)(163.4m)(257.7m)(93.1m)(159.6m)

Depreciation and Amortization

212.5k627.7k940.3k591.0k804.0k1.8m2.8m960.0k1.9m

Inventories

580.0k(20.8m)

Accounts Payable

(9.5m)
USDFY, 2017

Revenue/Employee

23.6k

Debt/Equity

-3.2 x

Debt/Assets

1.2 x

Financial Leverage

-2.7 x
Show all financial metrics

Immunomedics Operating Metrics

Immunomedics's Properties was reported to be 2 in FY, 2019.
FY, 2017FY, 2018FY, 2019Sep, 2020

Patents (US)

390

Phase I Trials Products

1 2

Phase III Trials Products

1 2 4

Properties

2 3 2
Show all operating metrics

Immunomedics Acquisitions / Subsidiaries

Company NameDateDeal Size
IBC Pharmaceuticals, Inc.
Immunomedics GmbH

Immunomedics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

73/100

SecurityScorecard logo

Immunomedics Revenue Breakdown

Embed Graph

Immunomedics revenue breakdown by business segment: 69.6% from Product sales, 15.3% from License fee and other revenues and 15.1% from Research and development

Human Capital Metrics

Embed Graph
Show all human capital metrics

Immunomedics Online and Social Media Presence

Embed Graph

Immunomedics News and Updates

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Immunomedics, Inc. Buyout

WILMINGTON, Del., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Immunomedics, Inc. (“Immunomedics”) (NASDAQ GS: IMMU) regarding possible breaches of fiduciary duties and other violations of law related to Immunomedics’ agreement to be acquired by …

Gilead to buy cancer drugmaker Immunomedics in $21 billion deal

The deal will provide Gilead access to Immunomedics' cancer treatment drug called Trodelvy, an FDA-approved treatment for metastatic triple-negative breast cancer.

Immunomedics Announces Key Oral Presentations at ESMO 2020

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced the presentation of five abstracts at ESMO Virtual Congress 2020, highlighted by oral presentations of the ASCENT study in metastatic tri…

Immunomedics to Participate in Upcoming Healthcare Conferences

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that Dr. Behzad Aghazadeh, Executive Chairman, is scheduled to participate in virtual fireside chats at the following healthcare conferenc…

(IMMU) Alert: Shareholder Class Action Against Immunomedics Survives Motion to Dismiss; Should Management be Held Accountable for Investors Losses? Contact Johnson Fistel

SAN DIEGO, Aug. 20, 2020 /PRNewswire/ -- Johnson Fistel, LLP is investigating potential claims on behalf of Immunomedics Inc. (NASDAQ: IMMU) ("Immunomedics" or the "Company") against certain of its officers and directors. Specifically, a class-action lawsuit pending in the United States...

Immunomedics Announces FDA Approval of Samsung Biologics as Antibody Manufacturer of Trodelvy

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has approved the Prior Approval Supplement (PAS) for Samsung Biologics to produce …
Show more

Immunomedics Blogs

Immunomedics Announces Leadership Change and Provides Business Update Amid COVID-19

The post Immunomedics Announces Leadership Change and Provides Business Update Amid COVID-19 appeared first on Immunomedics.

Immunomedics to Present New Trodelvy Data in Non-Breast Indications at the 2020 ASCO Virtual Meeting

The post Immunomedics to Present New Trodelvy Data in Non-Breast Indications at the 2020 ASCO Virtual Meeting appeared first on Immunomedics.

Immunomedics to Participate in BofA Securities 2020 Healthcare Conference

The post Immunomedics to Participate in BofA Securities 2020 Healthcare Conference appeared first on Immunomedics.

Immunomedics Reports First Quarter 2020 Results and Provides Corporate Update

The post Immunomedics Reports First Quarter 2020 Results and Provides Corporate Update appeared first on Immunomedics.

Immunomedics Announces Commercial Availability of Trodelvy in the United States

The post Immunomedics Announces Commercial Availability of Trodelvy in the United States appeared first on Immunomedics.

Immunomedics to Report First Quarter 2020 Results and Host Conference Call and Webcast on May 6, 2020

The post Immunomedics to Report First Quarter 2020 Results and Host Conference Call and Webcast on May 6, 2020 appeared first on Immunomedics.
Show more

Immunomedics Frequently Asked Questions

  • When was Immunomedics founded?

    Immunomedics was founded in 1982.

  • Who are Immunomedics key executives?

    Immunomedics's key executives are Behzad Aghazadeh, Usama Malik and Brendan Delaney.

  • How many employees does Immunomedics have?

    Immunomedics has 366 employees.

  • What is Immunomedics revenue?

    Latest Immunomedics annual revenue is $295 k.

  • What is Immunomedics revenue per employee?

    Latest Immunomedics revenue per employee is $806 .

  • Who are Immunomedics competitors?

    Competitors of Immunomedics include Novartis, ImmunoGen and AstraZeneca.

  • Where is Immunomedics headquarters?

    Immunomedics headquarters is located at 300 The American Rd, Morris Plains.

  • Where are Immunomedics offices?

    Immunomedics has offices in Morris Plains and Rödermark.

  • How many offices does Immunomedics have?

    Immunomedics has 2 offices.